BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 34480554)

  • 21. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer.
    Jordan VC; Brodie AM
    Steroids; 2007 Jan; 72(1):7-25. PubMed ID: 17169390
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effects of a novel hormonal breast cancer therapy, endoxifen, on the mouse skeleton.
    Gingery A; Subramaniam M; Pitel KS; Reese JM; Cicek M; Lindenmaier LB; Ingle JN; Goetz MP; Turner RT; Iwaniec UT; Spelsberg TC; Hawse JR
    PLoS One; 2014; 9(5):e98219. PubMed ID: 24853369
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Toxicity and adverse effects of Tamoxifen and other anti-estrogen drugs.
    Yang G; Nowsheen S; Aziz K; Georgakilas AG
    Pharmacol Ther; 2013 Sep; 139(3):392-404. PubMed ID: 23711794
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The St. Gallen Prize Lecture 2011: evolution of long-term adjuvant anti-hormone therapy: consequences and opportunities.
    Jordan VC; Obiorah I; Fan P; Kim HR; Ariazi E; Cunliffe H; Brauch H
    Breast; 2011 Oct; 20 Suppl 3(Suppl 3):S1-11. PubMed ID: 22015273
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estrogen-mediated mechanisms to control the growth and apoptosis of breast cancer cells: a translational research success story.
    McDaniel RE; Maximov PY; Jordan VC
    Vitam Horm; 2013; 93():1-49. PubMed ID: 23810002
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of the isomeric configuration and impurities of (Z)-endoxifen by 2D NMR, high resolution LC⬜MS, and quantitative HPLC analysis.
    Elkins P; Coleman D; Burgess J; Gardner M; Hines J; Scott B; Kroenke M; Larson J; Lightner M; Turner G; White J; Liu P
    J Pharm Biomed Anal; 2014 Jan; 88():174-9. PubMed ID: 24055701
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Limited predictive value of achieving beneficial plasma (Z)-endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer.
    Hennig EE; Piatkowska M; Karczmarski J; Goryca K; Brewczynska E; Jazwiec R; Kluska A; Omiotek R; Paziewska A; Dadlez M; Ostrowski J
    BMC Cancer; 2015 Aug; 15():570. PubMed ID: 26232141
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.
    Howell SJ; Johnston SR; Howell A
    Best Pract Res Clin Endocrinol Metab; 2004 Mar; 18(1):47-66. PubMed ID: 14687597
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Third annual William L. McGuire Memorial Lecture. "Studies on the estrogen receptor in breast cancer"--20 years as a target for the treatment and prevention of cancer.
    Jordan VC
    Breast Cancer Res Treat; 1995; 36(3):267-85. PubMed ID: 8573710
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Manipulating Estrogenic/Anti-Estrogenic Activity of Triphenylethylenes towards Development of Novel Anti-Neoplastic SERMs.
    Elnakib HE; Ramsis MM; Albably NO; Vector MA; Weigand JJ; Schwedtmann K; Wober J; Zierau O; Vollmer G; Abadi AH; Ahmed NS
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830456
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development and Characterization of Novel Endoxifen-Resistant Breast Cancer Cell Lines Highlight Numerous Differences from Tamoxifen-Resistant Models.
    Jones CJ; Subramaniam M; Emch MJ; Bruinsma ES; Ingle JN; Goetz MP; Hawse JR
    Mol Cancer Res; 2021 Jun; 19(6):1026-1039. PubMed ID: 33627502
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rethinking tamoxifen in the management of melanoma: New answers for an old question.
    Ribeiro MPC; Santos AE; Custódio JBA
    Eur J Pharmacol; 2015 Oct; 764():372-378. PubMed ID: 26165763
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis.
    Johnston SR; Boeddinghaus IM; Riddler S; Haynes BP; Hardcastle IR; Rowlands M; Grimshaw R; Jarman M; Dowsett M
    Cancer Res; 1999 Aug; 59(15):3646-51. PubMed ID: 10446976
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increasing tamoxifen dose in breast cancer patients based on CYP2D6 genotypes and endoxifen levels: effect on active metabolite isomers and the antiestrogenic activity score.
    Barginear MF; Jaremko M; Peter I; Yu C; Kasai Y; Kemeny M; Raptis G; Desnick RJ
    Clin Pharmacol Ther; 2011 Oct; 90(4):605-11. PubMed ID: 21900890
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Endoxifen shows promise in breast cancer.
    Cancer Discov; 2014 Feb; 4(2):OF1. PubMed ID: 24501306
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast.
    Pickar JH; Komm BS
    Post Reprod Health; 2015 Sep; 21(3):112-21. PubMed ID: 26289836
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
    Punglia RS; Burstein HJ; Winer EP; Weeks JC
    J Natl Cancer Inst; 2008 May; 100(9):642-8. PubMed ID: 18445827
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice.
    Ruddy KJ; Desantis SD; Gelman RS; Wu AH; Punglia RS; Mayer EL; Tolaney SM; Winer EP; Partridge AH; Burstein HJ
    Breast Cancer Res Treat; 2013 Oct; 141(3):421-7. PubMed ID: 24062210
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Progress in the prevention of breast cancer: concept to reality.
    Jordan VC
    J Steroid Biochem Mol Biol; 2000 Nov; 74(5):269-77. PubMed ID: 11162935
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel Selective Estrogen Receptor Ligand Conjugates Incorporating Endoxifen-Combretastatin and Cyclofenil-Combretastatin Hybrid Scaffolds: Synthesis and Biochemical Evaluation.
    Kelly PM; Keely NO; Bright SA; Yassin B; Ana G; Fayne D; Zisterer DM; Meegan MJ
    Molecules; 2017 Aug; 22(9):. PubMed ID: 28858267
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.